BioXcel Therapeutics, Inc. Other Nonoperating Income (Expense)
BioXcel Therapeutics, Inc. (BTAI) reported Other Nonoperating Income (Expense) of -$394.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-13
- BioXcel Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was -$394.00K, a 159.97% decline year-over-year.
- BioXcel Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $1.52M, a 76.84% decline year-over-year.
- BioXcel Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was $1.81M, a 45.06% decline year-over-year.
- BioXcel Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was -$12.55M, a 360.45% decline year-over-year.
- BioXcel Therapeutics, Inc. other nonoperating income (expense) for fiscal 2025 was -$3.52M, a 117.44% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. other nonoperating income (expense) for fiscal 2024 was $20.17M, a 5020.05% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. other nonoperating income (expense) for fiscal 2023 was $394.00K.
- BioXcel Therapeutics, Inc. other nonoperating income (expense) for fiscal 2022 was -$427.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$394.00K 10-Q · filed 2026-08-13 | $1.13M 10-Q · filed 2026-08-13 | $2.94M derived: sum of 3 quarters · filed 2026-08-13 | -$9.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.52M 10-Q · filed 2026-05-15 | $3.33M derived: sum of 2 quarters · filed 2026-05-15 | -$9.21M derived: sum of 3 quarters · filed 2026-05-15 | -$8.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$10.73M derived: sum of 2 quarters · filed 2026-03-27 | -$10.08M derived: sum of 3 quarters · filed 2026-08-13 | -$3.52M 10-K · filed 2026-03-27 |
| 2025-09-30 | -$12.55M 10-Q · filed 2025-11-12 | -$11.89M derived: sum of 2 quarters · filed 2026-08-13 | -$5.33M 10-Q · filed 2025-11-12 | -$2.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $657.00K 10-Q · filed 2026-08-13 | $7.22M 10-Q · filed 2026-08-13 | $10.51M derived: sum of 3 quarters · filed 2026-08-13 | $15.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $6.56M 10-Q · filed 2026-05-15 | $9.86M derived: sum of 2 quarters · filed 2026-05-15 | $14.67M derived: sum of 3 quarters · filed 2026-05-15 | $26.70M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $8.12M derived: sum of 2 quarters · filed 2026-03-27 | $20.14M derived: sum of 3 quarters · filed 2026-03-27 | $20.17M 10-K · filed 2026-03-27 |
| 2024-09-30 | $4.82M 10-Q · filed 2025-11-12 | $16.84M derived: sum of 2 quarters · filed 2025-11-12 | $16.88M 10-Q · filed 2025-11-12 | $16.98M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $12.03M 10-Q · filed 2025-08-12 | $12.06M 10-Q · filed 2025-08-12 | $12.17M derived: sum of 3 quarters · filed 2025-08-12 | $12.16M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $32.00K 10-Q · filed 2025-05-12 | $140.00K derived: sum of 2 quarters · filed 2025-05-12 | $135.00K derived: sum of 3 quarters · filed 2025-05-12 | $672.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $103.00K derived: sum of 2 quarters · filed 2025-03-28 | $640.00K derived: sum of 3 quarters · filed 2025-03-28 | $394.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | -$5.00K 10-Q · filed 2024-11-14 | $532.00K derived: sum of 2 quarters · filed 2024-11-14 | $286.00K 10-Q · filed 2024-11-14 | -$194.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $537.00K 10-Q · filed 2024-08-06 | $291.00K 10-Q · filed 2024-08-06 | -$189.00K derived: sum of 3 quarters · filed 2024-08-06 | -$127.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$246.00K 10-Q · filed 2024-05-09 | -$726.00K derived: sum of 2 quarters · filed 2024-05-09 | -$664.00K derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$418.00K derived: sum of 2 quarters · filed 2024-03-22 | -$427.00K 10-K · filed 2024-03-22 | |
| 2022-09-30 | $62.00K 10-Q · filed 2023-11-14 | $53.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |